Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous piggyBac-mediated anti-CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Japan Tissue Engineering
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous piggyBac-mediated anti-CD19 CAR-T cells are an investigational cell therapy designed to treat CD19-positive B-cell malignancies, primarily acute lymphoblastic leukemia (ALL). This therapy utilizes the piggyBac transposon system, a non-viral gene delivery platform, to stably integrate a chimeric antigen receptor (CAR) gene into a patient's own T cells. The CAR is engineered to recognize the CD19 antigen, a protein widely expressed on the surface of B-cell leukemia and lymphoma cells. By using a non-viral approach, developers aim to simplify the manufacturing process, reduce costs associated with viral vector production, and potentially generate T cells with a more robust memory phenotype. This specific program is being advanced through clinical trials in Japan, sponsored by the Japan Agency for Medical Research and Development (AMED) in collaboration with Nagoya University and Shinshu University, focusing on pediatric and adult patients with relapsed or refractory ALL.
- Other names
- piggyBac CAR-TpiggyBac-mediated anti-CD19 CAR-T cellspiggyBac-CD19-CAR-TpiggyBac-CD-19-CAR-TpiggyBac-CD 19-CAR-T
02
Targets
Beyond the preview
Go deeper on autologous piggyBac-mediated anti-CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous piggyBac-mediated anti-CD19 CAR-T cells.